Screener
Relmada Therapeutics, Inc. RLMD Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Research and development | $8,087,845 | $11,951,023 |
| General and administrative | 11,373,909 | 6,267,412 |
| Total operating expenses | 19,461,754 | 18,218,435 |
| Loss from operations | (19,461,754) | (18,218,435) |
| Other income: | ||
| Interest/investment income, net | 959,762 | 440,287 |
| Realized (loss)/gain on short-term investments | (9,867) | 62,952 |
| Unrealized (loss)/gain on short-term investments | (540,097) | 155,731 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s operating income?
- Relmada Therapeutics, Inc. (RLMD) reported operating income of -$19.46M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s operating income changed year-over-year?
- Relmada Therapeutics, Inc.'s operating income decreased by 6.8% year-over-year, from -$18.22M to -$19.46M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s operating income?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s operating income has grown at a -17.2% compound annual growth rate (CAGR), from -$125.7M to -$59.1M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Relmada Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude